Amicus Therapeutics Acquires Scioderm for $847,000,000

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b11874bf-4835-4bda-96a9-9fccc55d3ab5
Date
8/31/2015
Company Name
Scioderm
Mailing Address
1007 Slater Road Durham, NC 27703 USA
Company Description
The core business focus of Scioderm is the development of innovative dermatological drugs. Our strategy is to in-license or acquire early to mid-stage pharmaceutical products with the intent to develop the topical products.
Website
http://www.sderm.com
Transaction Type
M&A
Transaction Amount
$847,000,000
Transaction Round
Proceeds Purposes
M&A Terms
The $229 million upfront payment for Scioderm consists of $125 million in cash and $104 million in Amicus stock. Amicus will pay Scioderm shareholders another $361 million in cash or stock upon achievement of certain clinical and regulatory milestones and $257 million in cash or stock upon achievement of certain sales milestones.